Page 51 | Certara

Fact Sheet

Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA)

Whether you’re optimizing trial design or seeking strategic insights, Certara’s MBMA delivers the clarity and…

CertaraFebruary 19, 2025

Video

Driving Innovation in Pharmacometrics: An Interview with Wynand Smythe, Associate Director at Certara

CertaraFebruary 18, 2025

Blog

Streamline Clinical Data Publication Under EMA Policy 0070

February 14, 2025 The European Medicines Agency (EMA) Policy 0070 requires clinical data publication. Its…

CertaraFebruary 14, 2025

On-Demand Webinar

How to Modernize Patient Narrative Writing

Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…

CertaraFebruary 12, 2025

Live Events

12th Annual Cracow HTA Symposium

June 9-10, 2026 - Kraków - Join Europe’s leading HTA, payer, and policy experts. Explore EU…

CertaraFebruary 12, 2025

Video

Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling

Today’s drug candidates are more complex than ever. But with development decisions on the line,…

CertaraFebruary 12, 2025

Publication

Learn-confirm in model-informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform

Immunogenicity against therapeutic proteins frequently causes attrition owing to its potential impact on pharmacokinetics, pharmacodynamics,…

CertaraFebruary 10, 2025

Blog

EU CTIS: Europe’s New Clinical Trial Information System

The EU CTIS is now fully implemented, replacing EudraCT as the central hub for clinical…

CertaraFebruary 10, 2025

Poster

Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease

CertaraFebruary 7, 2025

Blog

Measuring metabolites in index clinical DDI studies

February 7, 2025A key drug development safety consideration is whether the drug candidate will interact…

CertaraFebruary 7, 2025

Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA)

Driving Innovation in Pharmacometrics: An Interview with Wynand Smythe, Associate Director at Certara

Streamline Clinical Data Publication Under EMA Policy 0070

How to Modernize Patient Narrative Writing

12th Annual Cracow HTA Symposium

Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling

Learn-confirm in model-informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform

EU CTIS: Europe’s New Clinical Trial Information System

Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease

Measuring metabolites in index clinical DDI studies

Newsletter sign up

Quick links

Solutions

Contact